NCT01875523View on ClinicalTrials.gov

PK of Serelaxin in Severe Renal Impairment and ESRD

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Renal Failure, ChronicEnd-Stage Renal Disease
Interventions
DRUG

Serelaxin

Trial Locations (1)

D-67269

Novartis Investigative Site, Grünstadt

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY